KISS1 receptor → GnRH → LH / FSH · Peptide
Evidence gap: Route-specific human PK and absolute bioavailability are not established in the imported material.
Open in the interactive library →Compare with other compounds →
Human studies use indication-specific IV or SC administration.
Context: Imported field-guide summary; primary citation incomplete.
Limitations: No universal testosterone-support protocol; specific primary trial not supplied.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Human
Human study regimen: Route: IV / SC; Species: Human
Limitations: No trial-specific amount, schedule, formulation or duration is supplied. No universal testosterone-support protocol is established.
A 2024 review reports that peripheral kisspeptin raises gonadotropins in humans; twice-daily subcutaneous kisspeptin-54 in hypothalamic amenorrhoea increased LH pulses but lost effect within 14 days through receptor desensitization; and an intravenous kisspeptin-10 test helped predict progression in delayed puberty.
Context: Narrative review of human studies.
Limitations: Review; doses and study sizes not given; summarizes cited human studies.
Open this exact record in the library →Suggest a correctionThese compounds share an Atlas pathway label. That is a navigation connection, not evidence of equivalent effects or suitability together.
Browse this pathway in the library →Educational research summary. Study amounts are research context, not a dose recommendation. Not medical advice.